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Abstract
Introduction The aim of our study was to identify new early
rheumatoid arthritis (RA) autoantibodies.
Methods Sera obtained from 110 early untreated RA patients
(<6 months) were analyzed by western blot using HL-60 cell
extract, separated on one-dimensional and two-dimensional gel
electrophoresis (1-DE, 2-DE). Sera from 50 healthy blood
donors and 20 patients with non-RA rheumatisms were used as
controls for 1-DE and 2-DE, respectively. The immunoreactive
proteins were identified by MALDI-TOF mass spectrometric
analysis and the presence of potential sites of citrullination in
each of these proteins was evaluated. FT-ICR mass
spectrometry was used to verify experimentally the effect of
citrullination upon the mass profile observed by MALDI-TOF
analysis.
Results The 110 1-DE patterns allowed detection of 10
recurrent immunoreactive bands of 33, 39, 43, 46, 51, 54, 58,
62, 67 and 70 kDa, which were further characterized by 2-DE
and proteomic analysis. Six proteins were already described RA
antigens: heterogeneous nuclear ribonucleoprotein A2/B1,
aldolase,  -enolase, calreticulin, 60 kDa heat shock protein
(HSP60) and BiP. Phosphoglycerate kinase 1 (PGK1), stress-
induced phosphoprotein 1 and the far upstream element-
binding proteins (FUSE-BP) 1 and 2 were identified as new
antigens. Post-translational protein modifications were analyzed
and potentially deiminated peptides were found on aldolase, -
enolase, PGK1, calreticulin, HSP60 and the FUSE-BPs. We
compared the reactivity of RA sera with citrullinated and
noncitrullinated -enolase and FUSE-BP linear peptides, and
showed that antigenicity of the FUSE-BP peptide was highly
dependent on citrullination. Interestingly, the anti-cyclic
citrullinated peptide antibody (anti-CCP2) status in RA serum at
inclusion was not correlated to the reactivity directed against
FUSE-BP citrullinated peptide.
Conclusions Two categories of antigens, enzymes of the
glycolytic family and molecular chaperones are also targeted by
the early untreated RA autoantibody response. For some of
them, and notably the FUSE-BPs, citrullination is involved in the
immunological tolerance breakdown observed earlier in RA
patients. Autoantibodies recognizing a citrullinated peptide from
FUSE-BP may enhance the sensibility for RA of the currently
available anti-CCP2 test.
1-DE: one-dimensional gel electrophoresis; 2-DE: two-dimensional gel electrophoresis; ACPA: anti-citrullinated protein antibodies; autoAb: autoan-
tibodies; CCP: cyclic citrullinated peptide; DTT: dithiothreitol; FCS: fetal calf serum; FT-ICR: Fourier transform ion cyclotron resonance; FUSE-BP: 
far-upstream element-binding protein; HSP60: 60 kDa heat shock protein; MALDI-TOF: matrix-assisted laser desorption/ionization–time of flight; MS: 
mass spectrometry; MW: molecular weight; PADI: peptidylarginine deiminase; PBS: phosphate-buffered saline; PGK: phosphoglycerate kinase; 
PTM: post-translational modification; RA: rheumatoid arthritis; VErA: Very Early Arthritis.Arthritis Research & Therapy    Vol 11 No 2    Goëb et al.
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Introduction
Rheumatoid arthritis (RA) is a disabling autoimmune and
inflammatory disease affecting between 0.3% and 1% of the
population in developed countries. The heterogeneity of
disease manifestations and the clinical course constitutes a
challenge for clinicians to predict the severity of the disease
and to choose the appropriate therapy early. The autoimmune
response appears early, often prior to the apparition of clinical
symptoms, and leads to the production of various autoantibod-
ies (autoAb) easily detectable in serum. These autoAb help to
understand pathological mechanisms and constitute biologi-
cal markers of the disease [1].
Furthermore, we recently assessed the contribution of several
genetic markers (HLA-shared epitope, TNFR2  196R and
PTPN22 1858T alleles) for RA diagnosis and found that the
autoimmune markers (rheumatoid factors and anti-citrullinated
protein antibodies (ACPA)) were the best parameters to pre-
dict RA diagnosis precociously [2]. ACPA have been originally
described as anti-keratin autoAb [3], anti-perinuclear autoAb
[4] and then as anti-filaggrin autoAb [5]. As a matter of fact,
ACPA recognize the deiminated form of filaggrin [6] and can
be detected using several peptide sequences in which
arginine is substituted with citrulline flanked by neutral amino
acids as antigens [7]. Whether filaggrin is the true autoantigen
of ACPA is unlikely since it is exclusively expressed in epithe-
lial cells, and other citrullinated proteins – such as fibrinogen
[8], vimentin [9], enolase [10], collagen type I [11], fibronectin
[12], a translational initiation factor [13] and even a viral pro-
tein, EBNA-1 [14] – have been shown to be the target of the
autoimmune response. The deimination of proteins is medi-
ated by peptidylarginine deiminase (PADI) and occurs notably
during cell death and oxidative stress [15,16], both events
observed in RA synovium.
Proteomic technologies rely on the ability to separate a com-
plex mixture of proteins and to identify them by different meth-
ods, in particular mass spectrometry (MS) using matrix-
assisted laser desorption/ionization–time of flight (MALDI-
TOF) analysis. Separated proteins are digested with enzymes
such as trypsin, then the peptide mass fingerprinting is used
to search sequence databases and to identify proteins that
match the observed fragment pattern. The identification of pro-
tein biomarkers specific for inflammatory diseases, and partic-
ularly for RA [17], may therefore provide highly sensitive
diagnosis tools and a better understanding of the mechanisms
underlying these disorders.
The present study was performed in order to identify new pro-
teins targeted by the early untreated RA autoimmune response
and their potential post-translational modifications (PTMs) that
could lead to the production of autoAb. These proteins were
identified after separating HL-60 extracts by two-dimensional
gel electrophoresis (2-DE) and localizing the antigens by
immunoblotting with patient sera. Protein spots were analyzed
by MALDI-TOF mass spectrometric analysis. In each of the dif-
ferent proteins highlighted, the presence of potential sites of
citrullination was investigated. Finally, the reactivity of RA
sera's autoAb against some citrullinated peptides correspond-
ing to the citrullinated antigens was assessed by Luminex
assay.
Materials and methods
Patients
Serum samples were collected from 110 RA patients among
the 314 very early arthritis patients recruited in the Very Early
Arthritis (VErA) cohort [18], including RA, non-RA well-defined
rheumatic diseases and undifferentiated polyarthritis. Briefly,
patients of the VErA cohort were required to have swelling of
at least two joints that had persisted for longer than 4 weeks
but had been evolving for less than 6 months, and who had not
received disease-modifying anti-rheumatic drugs and/or ster-
oid therapy before inclusion. All participants were European
Caucasians.
The Committee for Protection of Persons Participating in Bio-
medical Research of Rouen, France, approved the protocol.
All of the patients gave their informed consent for the study
(French law 88-1138; 20 December 1988). RA patients were
evaluated and classified using the American College of Rheu-
matology 1987 criteria for RA [19] at 2 years of follow-up.
Only sera collected at the time of inclusion (median duration of
the symptoms, 4 months) were analyzed in the present study.
Serum samples collected from 50 healthy blood donors and
20 patients with non-RA rheumatic diseases from the VErA
cohort were used as controls for one-dimensional gel electro-
phoresis (1-DE) and 2-DE, respectively.
Preparation of cell lysates
Since most RA autoantigens are ubiquitously expressed and
myeloid cells are the dominant cell type present in the rheuma-
toid joint, we selected HL-60, a human promyelocytic leukemia
cell line (American Collection of Cell Culture, Rockville, MD,
USA), for the present study. The HL-60 cell line was frozen in
FCS supplemented with 10% dimethyl sulfoxide, and was
kept in liquid nitrogen. In order to obtain cell lysates, HL-60
cells were thawed and grown in a large volume of complete
medium, RPMI 1640, sodium pyruvate 10%, FCS 10%, peni-
cillin–streptomycin 1% at 37°C in a humidified atmosphere
(5% CO2), then centrifuged, washed twice with sucrose, and
the pellet was frozen at -80°C until use. Proteins were
extracted according to Görg and colleagues [20], by precipi-
tation in organic solvent before being lysed in 9 M urea con-
taining 2% 3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), 20 mM dithiothreitol (DTT) and
protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO,
USA). The lysate was sonicated (Vibra Cell; Bioblock Scien-
tific, Illkirch, France), centrifuged at 15,000 rpm for 30 min at
4°C, and frozen at -80°C.Available online http://arthritis-research.com/content/11/2/R38
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One-dimensional gel electrophoresis and western 
blotting
HL-60 cells proteins were separated by 1-DE on 4% to 12%
precast Bis–Tris NuPAGE gels, using MOPS running buffer
(Invitrogen, Carlsbad, CA, USA). After separation, proteins
were transferred onto nitrocellulose membranes (Hybond™-c
extra; GE Healthcare Life Sciences, Piscataway, NY, USA)
and stained with Ponceau red (Sigma-Aldrich). Membranes
were cut and the strips were saturated with PBS–5% dry milk,
were incubated with patient sera (1:100 dilution), were incu-
bated with biotinylated conjugated mouse monoclonal anti-
human IgG (Fc) (Southern Biotechnology Associates Inc., Bir-
mingham, AL, USA), were incubated with alkaline phos-
phatase-conjugated streptavidin (CALTAG; Invitrogen), and
were revealed with NBT/BCIP (Roche Applied Science, Indi-
anapolis, IN, USA). Each step was followed by three washes
with PBS/Tween 0.05% buffer.
Data-processing analysis
One-dimensional immunoblotting patterns, given by sera from
110 RA patients and 50 healthy blood donors, were analyzed
with the Image Master TotalLab software (GE Healthcare Life
Sciences), in order to identify the various protein patterns after
background removal, and to measure the migration distance
and expression intensity of each band. Perl and R scripts were
developed for standardization of the molecular weight (MW)
and the expression level. Selected serum protein patterns
were then studied in further detail by 2-DE.
Two-dimensional gel electrophoresis
RA and non-RA control sera were analyzed by western blot
using 2-DE membranes. Proteins were focused at 20°C, with
11 cm immobilized pH 3 to 10 gradient IPG ReadyStrips
(BIO-RAD Laboratories, Hercules, CA, USA) that were incu-
bated for 16 hours in 200 l protein extract mixed with rehy-
dration buffer (8 M urea, 2% CHAPS, 1% DTT, trace of
bromophenol blue, 0.2% Biolyte carrier ampholytes 3 to 10;
BIO-RAD Laboratories). The Protean IEF cell (BIO-RAD Lab-
oratories) was used with fast-voltage ramping at a maximum
voltage of 6,000 V for 20 hours. After the first dimension run,
the strips were equilibrated by incubation in 6 M urea, 0.375
M Tris–HCl, pH 8.8, 2% SDS, 20% glycerol, 2.5% (w/v) DTT
10 ml per strip for 20 minutes at room temperature, followed
by an incubation for 30 minutes in the same buffer but in which
DTT was replaced by 2.5% (w/v) iodoacetamide. Strips were
then placed on the top of 4% to 12% Criterion™ XT precast
gels (11 cm × 8 cm × 1 mm) (BIO-RAD Laboratories) and
migrated constantly at 200 V until the bromophenol blue dye
front had reached the bottom of the gel. The BenchMark™
prestained protein ladder (Invitrogen) was used as the MW
standard in the second dimension step. In some experiments,
this ladder was replaced by the protein extract in order to vis-
ualize both 1-DE and 2-DE protein patterns on the same mem-
brane. Finally, gels were either stained with Coomassie brilliant
blue G250 (Sigma-Aldrich) or were electroblotted for 1 hour
onto nitrocellulose membranes, and western blotting analyses
were performed as previously described. G250-stained 2-DE
gels were scanned using a densitometer, and images were
obtained with digitalization software (2-D Phoretix, Alphelys
Plaisir, France). Immunoreactive spots were selected by com-
paring the immunoblotted replica with G250-stained gels.
Protein identification
The immunoreactive spots were excised from polyacrylamide
gels with Ettan Spot Picker (GE Healthcare Life Sciences) and
were digested by proteomics-grade trypsin (Sigma-Aldrich)
with Ettan Digester (GE Healthcare Life Sciences). After
digestion, peptides were extracted with 50% acetonitrile,
0.1% trifluoroacetic acid and mixed on the MALDI-TOF target
(Applied Biosystems, Foster City, CA, USA) with an equal
matrix volume of 7.5 mg/ml -cyano-4-hydroxy cinnamic acid
(LaserBio Labs, Sophia Antipolis, France) saturated with 50%
acetonitrile, 0.1% trifluoroacetic acid.
Samples were analyzed by mass spectrometry with a MALDI-
TOF Voyager-DE™ PRO (Applied Biosystems) using a
delayed ion extraction and ion mirror reflector mass spectrom-
eter. The instrument settings were: reflector mode with posi-
tive polarity, 100 nanosecond delay extraction time, 70% to
80% grid voltage and 20,000 V accelerating voltage. Laser
shots at 500 per spectrum were used to acquire one spectrum
with a mass range from 700 to 4,000 Da. External calibration
was carried out using the Proteomix–Peptide calibration Mix4
(LaserBio Labs). Spectra were accumulated manually from dif-
ferent acquisitions to improve resolution and the signal-to-
noise ratio.
The tools used to identify proteins from peptide mass finger-
printing data were Aldente and FindMod [21,22], which can
be found on the Expasy server [23]. By looking over differ-
ences between experimentally determined and theoretical
peptide masses from a specified protein, FindMod permits one
to discover PTMs and to make predictions as to what amino
acid in the peptide is likely to carry the modification. Several
possibilities were often suggested that stand within the
selected mass tolerance, but most of them could be eliminated
using a manual spectrum recalibration. The peptides were
generated by trypsin that cleaves proteins at the C-terminal
side of K or R. The number of missed cleavages allowed was
set to 1 for Aldente and was set up to 3 for FindMod analysis.
Several chemical modifications occurring during the separa-
tion process were taken into account in Aldente and FindMod
analysis: carboxyamidomethyl cysteine due to the action of
iodoacetamide on cysteine residues, propionamide cysteine
that is an acrylamide adduct to cysteine, and methionine sul-
foxide linked to the presence of ammonium persulfate in the
gel.Arthritis Research & Therapy    Vol 11 No 2    Goëb et al.
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Characterization of citrullination by mass fingerprinting
After the identification of immunoreactive proteins with the
Aldente program, the corresponding spectra were further
examined in order to detect the presence of several types of
PTM of discrete mass. The FindMod and FindPept programs
(Expasy server [23]) were used for looking at mass differences
between experimentally determined peptide masses and theo-
retical peptide masses. When a mass difference correspond-
ing to a known PTM was observed, rules were applied that
examine the sequence of the peptide of interest and make pre-
dictions as to which amino acid in the peptide was likely to
carry the modification. These rules are included either in the
FindMod and FindPept programs or in the various tools and
software for PTMs found on the Expasy server [23] (for
instance, NetPhos or NetAcet).
In our study, a particular attention was paid to citrullination, a
PTM occurring on arginine residues. Several rules were
applied: for one citrullinated arginine, the peptide theoretical
mass increase is 0.98 Da and the modified peptide, losing one
amino group, becomes more acidic [24]; citrullinated arginine
residues are not likely to be cleaved by trypsin, so that a mini-
mum number of one missed cleavage must be specified and a
peptide that includes a C-terminal citrullinated arginine must
be rejected; and in a biological sample, only a fraction of a
given protein may be citrullinated at a specific site. Because of
the several PTMs occurring on a given protein, this protein was
generally found on a two-dimensional map as a train of spots.
A spot separated by two-dimensional gel may thus contain the
same protein with several PTMs. Consequently, a citrullinated
peptide proposed by FindMod should incite one to search for
the modified and unmodified peptides in the spectra of this
protein, both peptides differing only by 0.98 Da generating an
unusual isotopic mass cluster.
Otherwise, to verify these specifications for the characteriza-
tion of citrullination by mass fingerprinting, we deiminated in
vitro aldolase purified from rabbit muscle (Sigma-Aldrich) with
PADI from rabbit skeletal muscle (Sigma-Aldrich). Then 25 g
purified aldolase were incubated with 0.2 units PADI in buffer
containing 0.1 M Tris–HCl, pH 7.4, 10 mM CaCl2, 5 mM DTT,
at 37°C for 90 minutes. The citrullination processes were fol-
lowed by 2-DE analysis, enzymatic digestion of the various cit-
rullinated aldolase obtained and analysis of the peptides by
MALDI-TOF MS and by Fourier transform ion cyclotron reso-
nance (FT-ICR) mass spectrometer.
Fourier transform ion cyclotron resonance mass 
spectrometer
The peptide sequence spectra were obtained using nanochro-
matography (Ultimate LC system, Dionex; LC-Packings,
Amsterdam, the Netherlands) online with an Apex Qe 9.4 T FT-
ICR mass spectrometer (Bruker Daltonics, Bremen, Ger-
many). Starting from a volume of 1 l peptide solution, pep-
tides were desalted and concentrated on a C18
preconcentration column (5 cm × 300 m) and separated on
a Pepmap C18 column (15 cm × 75 m) at 200 nl/min solvent
flow. The elution was performed using gradients of solvent A
(95% H2O, 5% acetonitrile, 0.1% HCOOH) and solvent B
(20% H2O, 80% acetonitrile, 0.1% HCOOH): 15 minutes in
100% solvent A, then solvent B was increased to 100% in
130 minutes, then kept at 100% for 15 minutes, and then
finally solvent B decreased to 0% in 5 minutes. The column
was allowed to equilibrate for 15 minutes before another run.
The FT-ICR mass spectrometer is equipped with a nano-elec-
trospray source. Detection was carried out in the positive
mode. A potential of 1.7 kV was applied on the needle. The
time cycle of an experiment for each spectrum, including accu-
mulation, transfer, excitation, detection and quench, ran for
approximately 3 seconds. In detail, ions were accumulated for
1 second in the hexapole, and 2 seconds in the quadrupole
collision cell; 0.0016 seconds was set for optics transfer and
0.01 seconds for the electronic dwell time. The detection
parameters were broadband detection, 512 K acquisition size,
and start mass at m/z 200 leading to 0.5243 seconds tran-
sient duration allowing theoretical resolution of 190,000 at m/
z 400. For the liquid chromatography–MS run, the quadrupole
was not resolving and set at m/z 350 and the collision energy
set at 1.5 eV. For liquid chromatography–MS/MS runs, the
quadrupole was resolving and set at the required mass m/z
824.2 and the collision energy set at 28.5 eV. The mass win-
dow of the selecting quadrupole was 2 mass units. Spectra
were annotated using the fragment algorithm in the Distiller
software from Matrixscience (Matrix Science Ltd., London,
UK), which allows introducing the required modifications
(deamidation, citrullination) on specific amino acids.
Detection of citrullinated proteins and deimination in 
vitro
After transfer, the membranes were saturated with blocking
buffer and were incubated with rabbit immunoaffinity purified
IgG anti-citrulline (Upstate Biotechnology, Lake Placid, NY,
USA). Biotinylated-goat anti-rabbit and IRDye 800-conjugated
streptavidin were used as secondary antibodies and were vis-
ualized using the Odyssey™ Infrared Imaging system (LI-COR
Biosciences, Lincoln, NE, USA) according to the manufac-
turer's protocol with minor modifications. In some experiments,
membranes were incubated with 2 units PADI from rabbit skel-
etal muscle (Sigma-Aldrich) in buffer containing 0.1 M Tris–
HCl, pH 7.4, 10 mM CaCl2, 5 mM DTT, overnight at 37°C.
Anti-citrullinated protein antibody detection
The presence of ACPA was detected using anti-cyclic citrulli-
nated peptide antibody (anti-CCP2) commercially available
kits (EuroImmun, GMBH, GroB Grönau, Germany). In the
present study, we have considered both ACPA positivity
(threshold, 10 arbitrary units) and the level measured during
the inclusion.Available online http://arthritis-research.com/content/11/2/R38
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Anti-peptide antibody detection
We designed six deiminated peptides using both linear citrull-
inated peptides and CCPs. Their sequences were determined
from those identified by MALDI-TOF MS analysis. In addition,
we introduced six histidines for coupling to LiquiChip Ni-NTA
beads (LiquiChip NiNTA; Qiagen, SA, Courtaboeuf, France).
For cyclic peptides, cysteine residues were added at each
extremity to create a disulfide bridge. All of the peptides were
purchased from Millegen (Labege, France). Ni-NTA beads
were incubated with peptides overnight. For antibody detec-
tion, beads mixed together were added to patient sera diluted
1:100 and were incubated at room temperature for 30 min-
utes. After a wash cycle, biotin-conjugated anti-human IgG
(Southern Biotechnological) was added for 30 minutes fol-
lowed by streptavidin-PE (Qiagen SA) for 15 minutes. The
bead mixture was analyzed by passing through the detector of
a Bio-Plex system (BIO-RAD, Marnes-la-Coquette, France)
that identifies the beads based on the fluorescence of the
dyes. The amount of antibody bound to the bead was deter-
mined by the fluorescence of PE. The fluorescence intensity
values obtained with noncitrullinated peptides were sub-
tracted from those observed with the corresponding citrulli-
nated peptides; a difference above 100 units of fluorescence
intensity was considered positive.
Statistical analysis
Wilcoxon nonparametric and Student parametric tests were
used to determine whether the presence and titer of ACPA
were associated with the presence of antibodies directed
against the 1-DE-separated polypeptide bands, and whether
the presence of antibodies directed against the highlighted
antigens was associated with that of antibodies directed
against corresponding synthetic citrullinated peptides. We
also assessed whether the presence of antibodies directed
against synthetic citrullinated peptides was correlated with the
presence of ACPA (anti-CCP2 test) at inclusion. For all tests,
P < 0.05 was considered statistically significant.
Results
Detection of autoantibodies in RA patient sera by 
western blot analysis
Figure 1
Detection of autoantibodies in rheumatoid arthritis patient sera Detection of autoantibodies in rheumatoid arthritis patient sera. Autoantibodies in rheumatoid arthritis (RA) patient sera were detected by western 
blot analysis using HL-60 cell extract as the substrate. (a) Example of one-dimensional gel electrophoresis western blot analysis with Imagemaster 
totalLab software to determine the molecular weights (m.w.) of different bands using an internal standard (is1 and is2) that correspond to 120-kDa 
and 80-kDa proteins revealed by alkaline phosphatase-conjugated streptavidin. These bands were used for standardization between the different 
membranes. (b) Virtual blot of the 110 RA patient sera. The m.w. of the bands are indicated on the right-hand side of the figure. Each vertical lane 
corresponds to different RA patient sera.Arthritis Research & Therapy    Vol 11 No 2    Goëb et al.
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As the first step of new disease-specific autoantibody detec-
tion, each of the 110 sera obtained at inclusion from RA
patients recruited into the VErA cohort was studied by western
blot analysis on HL-60 cell extract separated on 1-DE. All of
the membranes were analyzed by scanning densitometry and
the quantification of bands was normalized using internal
standards for each band (Figure 1a). Among the 110 patterns,
compared within the interval of 33 to 70 kDa, 10 bands of 33,
39, 43, 46, 51, 54, 58, 62, 67 and 70 kDa were recognized
by 31, 37, 4, 53, 9, 25, 11, 40, 14 and 9 RA sera, respectively.
Table 1 presents the reactivity of the 110 RA sera that was
compared with that of 50 control sera obtained from healthy
blood donors. Nine of the latter (9/50) bound to the p46
polypeptide, which corresponds to -enolase (see below).
Forty-one healthy sera (82%) were therefore clearly negative
with respect to -enolase recognition. A virtual representation
of the RA patterns is shown in Figure 1b.
Identification of immunoreactive spots
To elucidate the nature of proteins contained in these bands,
we performed target-oriented proteomics using the 2-DE-sep-
arated-HL60 protein map followed by western blot analysis
with RA sera selected on the basis of their 1-DE pattern. Fifty
RA sera were analyzed by two-dimensional PAGE to simulta-
neously visualize 1-DE bands and 2-DE immunoreactive spots
on the same membrane. An example of a RA serum recogniz-
ing both -enolase and heterogeneous nuclear ribonucleopro-
tein A2/B1 is shown in Figure 2a. All of the immunoreactive
spots were excised from polyacrylamide gel and digested by
trypsin. The peptides were analyzed by MS and were analyzed
using the Aldente and FindMod tools. The comparison of the
mass spectra obtained for each spot with those contained in
the Swiss-Prot database allowed us to identify with high prob-
ability the immunoreactive proteins. All of the identifications of
immunoreactive spots were obtained from three separate
experiments.
Table 2 presents the identities of the 10 immunoreactive spots
with their Aldente and Z scores, and summarizes all of the hits
(that is, the peak matching a theoretical peptide) and the cov-
erage found with both Aldente and FindMod software. We
therefore identified heterogeneous nuclear ribonucleoprotein
A2/B1 at 33 kDa, fructose-biphosphate aldolase A (aldolase)
and phosphoglycerate kinase 1 (PGK1) at 39/43 kDa, -eno-
lase and calreticulin at 46/51 kDa, 60 kDa heat shock protein
(HSP60) and stress-induced phosphoprotein 1 at 58/62 kDa,
and far upstream element-binding proteins 1 and 2 (FUSE-
BP1 and FUSE-BP2) and BiP, also named GRP78, at 67/70
Table 1
Reactivity of rheumatoid arthritis and healthy control sera with HL-60-derived proteins
HL-60-derived polypeptides
p33 p39 p43 p46 p51 p54 p58 p62 p67 p70
Rheumatoid arthritis sera (n = 110) 31 37 4 53 9 25 11 40 14 9
Control sera (n = 50) 0** 0** 0 9** 0 0** 3 15* 0** 6
Data expressed as the number of sera that bind the different polypeptides by western blot analysis. *0.002 <P < 0.005, **P < 0.0004.
Figure 2
Identification of proteins contained in the HL-60 cell map and bound by  rheumatoid arthritis sera Identification of proteins contained in the HL-60 cell map and bound by 
rheumatoid arthritis sera. (a) Western blot analysis of a rheumatoid 
arthritis (RA) serum recognizing both 50-kDa and 33-kDa proteins, 
using the Odyssey™ Infrared Imaging system. HL-60 cell lysates were 
separated by two-dimensional gel electrophoresis (2-DE) using 11 cm 
readyStrip™ IPG strips (pH 3 to 10, nonlinear) in the first dimension 
and precast Criterion XT Bis-Tris gels (4% to 12% resolving gels, 
IPG+1 well) in the second dimension. The protein extract was put in 
the one-dimensional well instead of the molecular weight (m.w.) to visu-
alize both the one-dimensional and two-dimensional patterns. The pro-
teins were electroblotted onto nitrocellulose membranes, then 
incubated with RA sera. (b) Immunoreactive spots were identified by 
mass spectrometry with a matrix-assisted laser desorption/ionization–
time of flight Voyager-DE™ using 2-DE-separated HL-60 protein maps, 
stained by Coomassie brilliant blue G250. 1-DE, one-dimensional gel 
electrophoresis; FUSE-BP, far-upstream element-binding protein; 
hnRNP A2/B1, heterogeneous nuclear ribonucleoprotein A2/B1; 
HSP60, 60 kDa heat shock protein; PGK1, phosphoglycerate kinase 1; 
StiP1, stress-induced phosphoprotein 1.Available online http://arthritis-research.com/content/11/2/R38
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kDa (Figure 2b). Since 2-DE separates proteins with identical
MW but different isoelectric points, several antigens were
identified for a given MW.
Among the 20 sera from non-RA rheumatic diseases of the
VErA cohort, two sera weakly recognized -enolase. These
two sera were obtained from patients who had undifferenti-
ated arthritis. Except for -enolase, the other immunoreactive
spots were never bound by any autoAb.
Characterization of citrullination by mass fingerprinting
After the identification of immunoreactive proteins with the
Aldente program, the corresponding spectra were further
examined in order to detect the presence of several types of
PTMs of discrete mass. Among the PTMs observed for most
of proteins, we focused our attention on potentially deiminated
peptides – we found that seven out of the 10 proteins (aldo-
lase, -enolase, PGK1, calreticulin, HSP60, FUSE-BP1 and
FUSE-BP2) possessed such peptides (Table 3).
In vitro citrullination of aldolase
To verify experimentally the effect of citrullination upon the
mass profile observed by MALDI-TOF analysis, we proceeded
with the in vitro deimination of aldolase purified from rabbit
muscle. Figure 3 shows the 2-DE maps of native and
citrullinated aldolase, respectively. The observed acidification
of the protein was correlated with the number of citrullinated
arginines. As citrullination of arginine abrogates the site of
trypsin cleavage, the number of digested peptides diminishes
with the rate of citrullination. This was expressed in mass spec-
tra whose peak scarcity was related to the isoelectric point
value of citrullinated aldolase (data not shown).
The modification of the isotopic mass cluster linked to citrulli-
nation is particularly well illustrated by the peptide correspond-
ing to (RLQSIGTENTEENR) of 1,646.81 Da (theoretical
mass). For spot 1, the isotopic cluster was classic with a first
peak that appears at 1,646.85 Da (Figure 3c). For spot 5, the
isotopic cluster is modified since the first peak is less intense
than the second one, which appears at 1,647.70 kDa, in rela-
tion to its citrullination (Figure 3d). It is noteworthy that all
Table 2
Identities of immunoreactive spots from MALDI-TOF spectra using the Aldente and FindMod tools
Protein Swiss-Prot number Theoretical MW 
(Da)/pI
Hitsa Coverage (%)b Aldente scorec Aldente Z scored
Aldente FindMod Aldente FindMod
Heterogeneous 
nuclear 
ribonucleoprotein A2/
B1
[Swiss-
Prot:P22626]
37,430/9.0 17 21 51 51 49.54 655.1
Aldolase [Swiss-
Prot:P04075]
39,288/8.4 22 60 69 86 44.36 814.8
Top of form 1 
phosphoglycerate 
kinase 1
[Swiss-
Prot:P00558]
44,728/8.3 15 25 40 54 21.20 416.8
-Enolase [Swiss-
Prot:P06733]
47,169/7.0 12 33 39 59 16.19 208.2
Calreticulin [Swiss-
Prot:P27797]
48,142/4.3 16 51 36 51 20.14 99.5
Heat shock protein 
60
[Swiss-
Prot:P10809]
61,055/5.7 26 41 52 64 107.28 1389
Stress-induced 
phosphoprotein 1
[Swiss-
Prot:P31948]
62,638/6.4 19 31 38 49 36.04 898.2
FUSE-BP1 [Swiss-
Prot:Q96AE4]
67,474/7.2 15 23 30 35 41.78 402.7
FUSE-BP2 [Swiss-
Prot:Q92945]
72,708/8.2 12 23 22 25 13.64 171.4
BiP [Swiss-
Prot:P11021]
72,334/5.1 25 34 44 47 94.41 1616.3
FUSE-BP, far-upstream element-binding protein; MALDI-TOF, matrix-assisted laser desorption/ionization–time of flight; MW, molecular weight; pI, 
isoelectric point. aA hit is an experimental peak matching a theoretical peptide. bThe coverage is the number of amino acids present in at least one 
peptide/the number of amino acids of the protein. cThe Aldente tool gives a score to each identified protein. The parameters selected in these 
scores are the number and the intensity of hits, the number of missed cleavages, the C-terminal amino acid, the chemical modifications and, at the 
protein level, the coverage of the identified peptides on the sequence. The score of the proteins identified in this study are largely greater than the 
score of the best random protein. dThe Z score is the number of standard deviations for a given score from the mean random score.Arthritis Research & Therapy    Vol 11 No 2    Goëb et al.
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these observations are valid for in vitro aldolase citrullination
and can be extended to the HL-60 cell extract as well.
Fourier transform ion cyclotron resonance mass 
spectrometer
After digestion of the spots by trypsin, in-gel nano-liquid chro-
matography–MS/MS analysis was performed on a nano-ESI-
Q-FT-ICR instrument (Model: Apex Q-e, Bruker, Bremen, Ger-
many) with the quadrupole analyzer set at the fixed mass m/z
824, a mass window of m/z ± 2 and a collision energy of 28.5
eV. A major peak was found in each gel spot. The mass of the
parent ion was ascertained from liquid chromatography/MS
performed at 1.5 eV collision energy and the quadrupole not
resolving in Radio-Frequency-only mode.
The three peaks are discharged ions at m/z 823.910, m/z
824,401 and m/z 824,403 respectively. The first peak there-
fore corresponds to a native peptide, whereas the second and
the third peaks, a mass unit higher, are deamidated or citrulli-
nated. Unfortunately these are two peptides with exactly the
same mass corresponding to the sequences 43 to 56
RLQSIGTENTEENR and 44 to 57 LQSIGTENTEENRR,
which differ only by the position of the R residue either at the
N-terminal or C-terminal position (theoretical m/z 823.908 for
the native peptide, and theoretical m/z 824.403 for the deam-
inated or citrullinated).
Inspection of the MS/MS spectra allows ascertaining the
sequences since a long y series is present on each MS/MS
spectrum (see Table 4). The first peak may therefore be attrib-
uted to a mixture of native LQSIGTENTEENRR and
RLQSIGTENTEENR. The second peak to LQSIGTEN-
TEE(NRR) bears a deamidation or citrullination on the NRR
sequence. As the first y ion detected is y3, the precise position
and therefore the nature of the modification cannot be ascer-
tained. We were pleased that the third peak may be unambig-
uously assigned to RLQSIGTENTEENR bearing a
citrullination on the R residue on the N-terminal side. Finally,
we must point out that other citrullinated peptides have been
identified corresponding to the sequence RALANSLACQGK
(sequence 331 to 342).
Detection of citrullinated proteins on two-dimensional 
gel electrophoresis protein maps
Differentiated HL-60 cells have been previously shown to
express PADI [24,25]. To assess the presence of citrullinated
peptides in HL-60-derived proteins, we used anti-citrulline
antibodies to immunoscreen HL-60 protein maps by western
blot analysis. On the replicas of these maps, several spots
were consistently detected by anti-citrulline antibodies (Figure
4a); in particular, spots previously characterized as -enolase,
aldolase and, at a lower level, HSP60 and FUSE-BP2. In
another set of experiments, HL-60 protein maps were incu-
bated with PADI for one night at 37°C. On these PADI-treated
membranes, HSP60 and FUSE-BP2 were brighter and PGK1
was also revealed by anti-citrulline antibodies, suggesting that
it effectively possesses citrullination sites (Figure 4b). It could
be noted that the spots corresponding to heterogeneous
nuclear ribonucleoprotein A2/B1 reacted with conjugate
alone and represent a false positive reaction (Figure 4c).
RA autoantibody reactivities against newly created 
citrullinated peptides
To confirm the antigenic structure that was targeted by autoAb
present in RA sera, we analyzed their reactivity against the cit-
rullinated peptides identified by MALDI-TOF MS analysis on
the different deiminated proteins (aldolase, -enolase, PGK1,
HSP60, FUSE-BP1 and FUSE-BP2), although it was
expected that not all identified sequences described in Table
3 were, or carried, B-cell epitopes. Interestingly, we noticed a
significant association between the presence of anti-p46 anti-
bodies and the reactivity against the peptide derived from -
enolase (P = 0.0047), between the presence of anti-p62 and
reactivity against HSP60 peptide (P = 0.016), and between
the presence of anti-p67 and reactivity against FUSE-BP2
peptide (P = 0.04), which confirms the identities of these
Table 3
Potentially deiminated peptides from MALDI-TOF spectra using the Aldente and FindMod tools
Protein Sequence of peptides Theoretical molecular weight (Da) Position Missing cleavage
Aldolase KDGADFAKWRcitrCVLK 1,856.921 139 to 152 3
Phosphoglycerate kinase 1 ALESPERcitrPFLAILGGAK 1,769.979 199 to 215 1
-Enolase YNQLLRcitrIEEELGSKAK 1,892.012 406 to 421 2
Calreticulin DKQDEEQRcitrLK 1,336.623 359 to 368 2
Heat shock protein 60 KDRcitrVTDALNATR 1,360.718 418 to 429 2
RcitrGVMLAVDAVIAELKK 1,729.988 142 to 157 2
FUSE-BP1 VPDGMVGFIIGRcitrGGEQISR 2,003.038 106 to 124 1
FUSE-BP2 TSMTEEYRVPDGMVGLIIGRGGEQINK (one 
of these R is citrullinated)
2,967.475 143 to 169 2
FUSE-BP, far-upstream element-binding protein; MALDI-TOF, matrix-assisted laser desorption/ionization–time of flight.Available online http://arthritis-research.com/content/11/2/R38
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polypeptides and may suggest that they could represent anti-
genic determinants recognized by RA autoAb.
With this regard, additional experiments were performed to
confirm that the antigenicity of the selected peptides was due
to the presence of citrulline. We focused on two peptides, the
first (YNQLLRcitrIEEELGSKAK) derived from -enolase and
the second from the FUSE-BP proteins, a peptide similar to
FUSE-BP1 and FUSE-BP2 that is certainly the most interest-
ing candidate autoantigen since the others were previously
shown to be recognized by RA sera. In this respect, we com-
pared the reactivity of RA sera with citrullinated and noncitrull-
inated -enolase and FUSE-BP linear peptides. The results
shown in Figure 5 clearly indicate that antigenicity of the
FUSE-BP peptide is highly dependent on citrullination, while
there was no difference concerning the reactivity against the
native and citrullinated forms of the -enolase peptide.
Relationship between ACPA, reactivity pattern against 
proteins and peptide binding
Since the ACPA assay is thought to detect most antibodies
directed against citrullinated peptides, we expected to find a
significant association between the titers of ACPA and the
presence of autoAb directed against 1-DE bands correspond-
ing to citrullinated proteins. A significant association was
therefore observed between ACPA titers and the presence of
Figure 3
Two-dimensional gel electrophoresis maps of native and citrullinated rabbit aldolase Two-dimensional gel electrophoresis maps of native and citrullinated rabbit aldolase. Two-dimensional gel electrophoresis maps of (a) native rabbit 
aldolase and (b) citrullinated rabbit aldolase. Mass spectra of (c) digested spot 1 and (d) digested spot 5. The isotope clusters correspond to the 
peptide RLQSIGTENTEENR with a mass of 1,646.809 Da for the peptide without post-translational modification and of 1,660.825 for the methyl-
ated peptide. The intensity increase observed for the second peak of the isotopic clusters in (d) is linked to the rate of acidification of the protein; this 
indicates the citrullination process. Beyond the fifth spot in (b), the rabbit aldolase is too citrullinated for the peptide RLQSIGTENTEENR to be seen 
after the trypsin digestion. m.w., molecular weight; pI, isoelectric point.Arthritis Research & Therapy    Vol 11 No 2    Goëb et al.
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autoAb, which respectively bound to p39 (P = 0.02), to p46
(P = 0.05), to p58 (P = 0.04) and to p62 (P = 0.03).
We observed that ACPA presence or absence in RA serum at
inclusion, however, was not totally correlated to the reactivity
directed against the citrullinated peptides. Indeed, among the
36 RA sera that were positive for ACPA at inclusion, 20 of the
sera did not possess any autoAb directed against the citrulli-
nated peptides. Conversely, among the 74 RA sera that were
negative for ACPA at inclusion, we observed that 18 (24%) of
the sera possessed autoAb against FUSE-BP peptide. A total
of 54 patients, from the 110 diagnosed as having RA after 2
years of follow-up, were therefore positive at inclusion either
for CCP2 ELISA or for FUSE-BP-derived peptide, thus giving
a percentage of 49% of ACPA-positive patients.
Discussion
The objective of the present study was to identify new autoan-
tibody markers in RA. For this purpose, we characterized the
antigens targeted by autoAb present in sera obtained from
early untreated RA patients, using 1-DE-separated and 2-DE-
separated HL-60 cell extracts followed by in-gel proteolytic
digestion and MALDI-TOF mass spectrometric analysis.
Ten proteins were shown to be frequently recognized by RA
antibodies and were subsequently identified. Six of these pro-
teins corresponded to already-described RA antigens – heter-
ogeneous nuclear ribonucleoprotein A2/B1 [26,27], aldolase
[28],  -enolase [29], calreticulin [30,31], BiP [32,33] and
HSP60 [34,35] – demonstrating the validity of our methodol-
ogy approach. Four other proteins – PGK1, stress-induced
phosphoprotein 1 and FUSE-BP1 and FUSE-BP2 – consti-
tute new candidate RA autoAb targets. A detailed analysis of
MS spectra enabled us to show that seven of these antigens
contain potentially deiminated peptides: aldolase, -enolase,
PGK1, calreticulin, HSP60, FUSE-BP1 and FUSE-BP2.
Western blot analysis confirmed the presence of such resi-
dues in aldolase, -enolase, HSP60 and FUSE-BP1 and con-
firmed the ability of another autoantigen, PGK1, to be
citrullinated in vitro.
A significant association was observed between ACPA posi-
tivity and titer and the reactivity of RA sera against p39, p46,
p58 and p62, which indirectly argues for the involvement of
antibodies directed against citrulline-containing sequences in
these anti-polypeptide reactivities. These data led us to ana-
lyze the reactivity against noncitrullinated peptides and citrull-
inated peptides derived from the different proteins, and our
interest was focused on two peptides derived from -enolase
and FUSE-BP with the hypothesis that these two citrullinated
peptides may represent new antigenic determinants. Firstly,
the reactivity of RA sera against the -enolase peptide
selected by MALDI-TOF data is not related to citrullination.
This result is not surprising since this peptide (YNQLLR-
citrIEEELGSKAK) is not an immunodominant citrullinated
epitope recognized by autoAb directed against citrullinated -
enolase. Indeed, in a recent report Lundberg and colleagues
have demonstrated that the RA antibody response to human
citrullinated -enolase is directed against an immunodominant
peptide (peptide 1A), different from that identified in the
Table 4
Fourier transform ion cyclotron resonance spectra of citrullinated aldolase
Peptide sequencea Peak 1a Peak 1b Peak 2 Peak 3
Sequence 1 Sequence 2 Sequence 3 Sequence 4
y1 175.119 175.119 175.119 175.119
y2 331.220 331.220 289.162 289.162
y3 445.263 446.247 418.204 418.204 445.269 446.247 418.197
y4 574.306 575.290 547.247 547.247 574.312 574.312 575.280 547.248
y5 703.348 704.332 648.295 648.295 648.294 703.347 704.336 648.297
y6 804.396 805.380 762.338 762.338 762.336 805.381 762.340
y7 918.439 919.423 891.380 891.380 891.386 918.455 919.425 891.391
y8 1,047.481 1,048.465 992.428 992.428 0.000 1,048.472 0.000
y9 1,148.529 1,149.513 1,049.449 1,049.449 1,049.449 1,149.496 1,049.454
y10 1,205.551 1,206.535 1,162.533 1,162.533 1,162.529 1,206.535 1,162.535
y11 1,318.365 1,319.619 1,249.565 1,249.565 1,249.563 0.000 1,249.569
y12 1,405.667 1,406.651 1,377.264 1,377.264 1,406.656
y13 1,533.725 1,534.709 1,490.708 1,490.708
aSequence 1, LQSIGTENTEENRR; Sequence 2, LQSIGTENTEE(N)RR; Sequence 3, RLQSIGTENTEENR; Sequence 4, (R)LQSIGTENTEENR.Available online http://arthritis-research.com/content/11/2/R38
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present study and one that cross-reacts with that recognizing
Porphyromonas gingivalis enolase [36]. Interestingly, our dif-
ferent experiments suggest that a citrullinated peptide derived
from the FUSE-BPs constitutes a new B-cell epitope of the RA
autoimmune response. Indeed, the role of citrulline in the anti-
FUSE-BP antibody response was demonstrated herein by the
lower reactivity to the arginine-containing control peptide. Fur-
thermore, the citrulline residue of this peptide is flanked by gly-
cine amino acids that have been shown to enhance ACPA
recognition and binding like serine residues [37]. Pertinently,
this citrullinated FUSE-BP peptide provide additional informa-
tion to ACPA since 24% of very early RA patients negative for
ACPA possessed autoAb against this peptide. Further studies
are needed to replicate these results but they do suggest that
this autoAb population may enhance sensibility of the current
anti-CCP2 test.
Citrullinated vimentin has been shown to be targeted by RA
a u t o i m m u n e  r e s p o n s e  a n d  t o  b e  a  p a r t  o f  t h e  S a  s y s t e m
[9,38]. Furthermore, the interest of antibodies to mutated cit-
rullinated vimentin for diagnosing rheumatoid arthritis in anti-
CCP-negative patients and for monitoring infliximab therapy
was recently suggested [39]. In our study, we did not find any
antibodies against citrullinated vimentin. Unmodified vimentin
is therefore present in our HL-60 protein map and was identi-
fied with MS at a MW of 53 kDa and an isolectric point of 5.1
(data not shown). Using our HL-60 cell extract, however,
vimentin was not detected by rabbit anti-citrulline antibodies.
The lack of citrullination of the vimentin contained in the HL-60
cell extract might thus explain why citrullinated vimentin was
not identified in our study as a target of early RA patient sera.
This proteomic approach allows one to demonstrate, on the
one hand, that the autoAb response in early untreated RA is
also directed against two categories of antigens, some
enzymes of the glycolytic family and chaperones; and, on the
other hand, that citrullination is involved in the antigenic prop-
erties of some of these antigens. The glycolytic enzyme family
appears to play an important role in the autoimmune response
observed in both RA and the RA experimental model. Indeed,
aldolase and -enolase have been already described as
autoantigens in RA [28,29]; and in the K/BxN mouse model,
Figure 4
Detection of citrullinated proteins on two-dimensional gel electrophore- sis HL-60 protein maps Detection of citrullinated proteins on two-dimensional gel electrophore-
sis HL-60 protein maps. Citrullinated proteins were detected on two-
dimensional gel electrophoresis HL-60 protein maps (a) before and (b) 
after treatment with peptidyl-arginine deiminase. The membranes were 
incubated with rabbit anti-citrulline antibodies, washed and then incu-
bated with biotinylated-goat anti-rabbit antibodies followed by IRDye 
800-conjugated streptavidin, and were visualized using the Odyssey™ 
Infrared Imaging system. FUSE-BP, far-upstream element-binding pro-
tein; HnRNP A2/B1, heterogeneous nuclear ribonucleoprotein A2/B1; 
HSP60, 60 kDa heat shock protein; m.w., molecular weight; PGK, 
phosphoglycerate kinase 1.
Figure 5
IgG response of rheumatoid arthritis sera to noncitrullinated and citrulli- nated linear peptides IgG response of rheumatoid arthritis sera to noncitrullinated and citrulli-
nated linear peptides. The IgG response of the 110 rheumatoid arthritis 
sera to noncitrullinated (NC) and citrullinated (C) linear peptides was 
detected using Luminex technology. These peptides derived from -
enolase (YNQLLRcitrIEEELGSKAK) and from far upstream element-
binding protein (FUSE-BP) (VPDGMVGFIIGRcitrGGEQISR). FUSE-BP, 
far-upstream element-binding protein.Arthritis Research & Therapy    Vol 11 No 2    Goëb et al.
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arthritis is induced by pathogenic autoAb directed against
another glycolytic enzyme, the glucose-6-phosphate isomer-
ase [40]. The role of citrullination in the recognition of -eno-
lase by RA patient-derived autoAb has been reported [10]. In
addition, our study indicates that both aldolase and PGK1 also
contain deiminated peptides, suggesting that the recognition
of glycolytic enzymes by RA sera is associated with their
potential to undergo this post-translational modification.
Calreticulin, HSP60 and BiP are molecular chaperones pro-
moting folding and oligomeric assembly of newly synthesized
polypeptides in endoplasmic reticulum [41]. They also consti-
tute targets of the autoimmune response in RA and systemic
lupus erythematosus [42]. Stress-induced phosphoprotein 1
(also called Hop) acts as an adaptor that directs heat shock
protein 90 to heat shock protein 70 protein complexes and
can modulate the chaperone activities of these heat shock
proteins [43].
c-myc is a proto-oncogene considered a master regulator of
cell proliferation, growth, differentiation, senescence and
death [44]. The far-upstream element of the human c-myc
gene stimulates promoter activity when bound by a trans-act-
ing protein [45] such as members of the FUSE-BP family [46].
These nuclear proteins are expressed in proliferating cells of
various lineages but not in quiescent cells [45,47]. In RA, syn-
ovial tissue fibroblast hyperplasia is reminiscent of tumor-like
proliferation, and fibroblasts exhibit elevated gene expression
of proto-oncogenes such as c-myc [48,49] – suggesting that
the FUSE-BPs could be overexpressed in these cells, which
could lead to the production of autoAb. Citrullination of pro-
teins is mediated by PADI, which converts peptidylarginine
into citrulline. It is thought to occur under extreme conditions,
such as stress, apoptosis [50,51] and inflammation [52], and
then to inactivate the function of a protein as shown by in vitro
experiments. In this regard, Sawada and colleagues showed
that the tumor suppressor p53, present in a citrullinated form
in RA synovial fibroblasts, loses its function and may partici-
pate in the tumor-like growth of RA synovium [53]. Citrullina-
tion of the FUSE-BPs, by deregulating c-myc, might then
contribute to the RA synovial hyperplasia.
Conclusions
The presented proteomic approach shows that two categories
of antigens, enzymes of the glycolytic family and molecular
chaperones are also targeted by the early untreated RA
autoAb response. For some of these, and notably the FUSE-
binding proteins, citrullination is involved in the immunological
tolerance breakdown observed earlier in RA patients. Our
results also point out that autoAb recognizing a citrullinated
peptide from FUSE-BP may enhance the sensibility for RA of
the current available anti-CCP2 test. An extensive study of the
prevalence of antibodies directed against peptides derived
from these new autoantigens is underway to precisely deter-
mine their predictive values in RA diagnosis and prognosis.
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